Key result
Selective ETA receptor antagonism with BQ-123 reduced mean arterial pressure by 13% (P<0.01 vs placebo) and increased renal blood flow by 38.8% in hypertensive chronic renal failure.
Why the study?
Do selective ETA, selective ETB, and combined ETA/B receptor antagonists reduce blood pressure and improve renal hemodynamics in hypertensive patients with chronic renal failure?
Population
16 participants (8 hypertensive patients with chronic renal failure and 8 matched healthy controls)
Comparison
Selective ET receptor antagonists BQ-123 and… vs Placebo (in a 4-way crossover design)
Design
RCT, randomized, 4-way crossover, double-blind
Follow-up
acute
Authors
Loading...
Supports selective ETA antagonism for BP reduction and renal perfusion in hypertensive CRF; confirms ET pathway as viable therapeutic target.
RCT (n=16)
Double-blind
4-way crossover
Do selective ETA, selective ETB, and combined ETA/B receptor antagonists reduce blood pressure and improve renal hemodynamics in hypertensive patients with chronic renal failure?
p-value: p=<0.01
Selective ETA receptor antagonism effectively lowers blood pressure and improves renal hemodynamics in hypertensive CRF patients, while combined ETA/B blockade lacks these renal benefits.
Goddard et al. (2004) conducted an RCT in Hypertensive chronic renal failure (n=16). BQ-123 (ETA) and BQ-788 (ETB) vs. Placebo was evaluated on Mean arterial pressure (p=<0.01). Selective ETA receptor antagonism with BQ-123 reduced mean arterial pressure by 13% (P<0.01 vs placebo) and increased renal blood flow by 38.8% in hypertensive chronic renal failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: